GlucoTrack (GlucoTrack) EBIT : $-8.77 Mil (TTM As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack EBIT?

GlucoTrack's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.95 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-8.77 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GlucoTrack's annualized ROC % for the quarter that ended in Mar. 2024 was -1,752.64%. GlucoTrack's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -12,692.47%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GlucoTrack's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -58.11%.

GlucoTrack EBIT Historical Data

The historical data trend for GlucoTrack's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack EBIT Chart

GlucoTrack Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-3.51

-3.13

-3.98

-4.43

-7.10

GlucoTrack Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-1.28	-1.18	-2.22	-2.42	-2.95

Competitive Comparison of GlucoTrack's EBIT

For the Medical Instruments & Supplies subindustry, GlucoTrack's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlucoTrack's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, GlucoTrack's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GlucoTrack's EV-to-EBIT falls into.

GlucoTrack EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.77 Mil.

GlucoTrack (NAS:GCTK) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GlucoTrack's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-11.804 * ( 1 - 0% )	/	( (0.71	+	0.637)	/ 2 )
=	-11.804	/	0.6735
=	-1,752.64 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.905	-	0.839	-	( 4.492	-	max(0, 1.512	-	4.868	+	4.492	))
=	0.71

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	2.106	-	1.014	-	( 1.497	-	max(0, 1.482	-	1.937	+	1.497	))
=	0.637

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

GlucoTrack's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-11.804	/	( ( (0.027 + max(-1.136, 0))	+	(0.159 + max(-1.018, 0)) )	/	2 )
=	-11.804	/	( ( 0.027	+	0.159 )	/	2 )
=	-11.804	/	0.093
=	-12,692.47 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.376)	-	(0.839	+	0	+	0.673)
=	-1.136

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.44)	-	(1.014	+	0	+	0.444)
=	-1.018

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GlucoTrack's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-8.771	/	15.094
	=	-58.11 %

GlucoTrack EBIT Related Terms

Thank you for viewing the detailed overview of GlucoTrack's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GlucoTrack (GlucoTrack) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070

Website

https://www.glucotrack.com

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It also focuses on developing a wireless module for transmission of measurement data captured by the GlucoTrack model DF-F to a cloud-based server.

Executives

James S Cardwell	officer: Chief Financial Officer	CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter	director	301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig	director	301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps	director	C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
Drew Sycoff	director	C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
David Podwalski	officer: Chief Commercial Officer	19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham	director, officer: Chief Executive Officer	19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun	officer: Chief Financial Officer	39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff	director	1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz	director	19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Angela Strand Boydston	director	C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Leslie Seff	director	PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Eran Hertz	officer: Chief Financial Officer	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich	director	C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100